ImmunityBio

ImmunityBio is a leading clinical-stage immunotherapy company developing next-generation therapies to drive immune mechanisms for the treatment of cancer and infectious diseases. The company’s portfolio of immunotherapies and cell therapy platforms aims to drive and sustain immune responses to create long-lasting and safe disease protection. These platforms and their associated product candidates are designed to be more effective, easier to use, and simpler to administer than the current standards of care in oncology and infectious diseases.